Haematologica (Feb 2018)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
- Christoph Schmid,
- Liesbeth C. de Wreede,
- Anja van Biezen,
- Jürgen Finke,
- Gerhard Ehninger,
- Arnold Ganser,
- Liisa Volin,
- Dietger Niederwieser,
- Dietrich Beelen,
- Paolo Alessandrino,
- Lothar Kanz,
- Michael Schleuning,
- Jakob Passweg,
- Hendrik Veelken,
- Johan Maertens,
- Jan J. Cornelissen,
- Didier Blaise,
- Martin Gramatzki,
- Noel Milpied,
- Ibrahim Yakoub-Agha,
- Ghulam Mufti,
- Montserrat Rovira,
- Renate Arnold,
- Theo de Witte,
- Marie Robin,
- Nikolaus Kröger
Affiliations
- Christoph Schmid
- Department of Hematology and Oncology, Klinikum Augsburg, University of Munich, Augsburg, Germany
- Liesbeth C. de Wreede
- Department of Medical Statistics & Bioinformatics, Leiden University Medical Center, the Netherlands;DKMS, German Bone Marrow Donor Center, Germany
- Anja van Biezen
- Department of Medical Statistics & Bioinformatics, Leiden University Medical Center, the Netherlands
- Jürgen Finke
- Department of Medicine 1, Hematology and Oncology, University of Freiburg, Germany
- Gerhard Ehninger
- Medizinische Klinik und Poliklinik I, Universitaets-Klinikum Dresden, Germany
- Arnold Ganser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
- Liisa Volin
- Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland
- Dietger Niederwieser
- Division of Hematology, Oncology and Hemostaseology, University Hospital Leipzig, Germany
- Dietrich Beelen
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
- Paolo Alessandrino
- Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Lothar Kanz
- Medizinische Klinik II, Universität Tübingen, Germany
- Michael Schleuning
- KMT Zentrum, Deutsche Klinik für Diagnostik, Wiesbaden, Germany
- Jakob Passweg
- Department of Hematology, University Hospital, Basel, Switzerland
- Hendrik Veelken
- BMT Center Leiden, Leiden University Hospital, the Netherlands
- Johan Maertens
- Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
- Jan J. Cornelissen
- Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
- Didier Blaise
- Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
- Martin Gramatzki
- Division of Stem Cell Transplantation and Immunotherapy, University Hospital Schleswig-Holstein Campus, Kiel, Germany
- Noel Milpied
- CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France
- Ibrahim Yakoub-Agha
- Hôpital Huriez, CHRU, Lille, France
- Ghulam Mufti
- Department of Hematological Medicine, GKT School of Medicine, London, UK
- Montserrat Rovira
- Institute of Hematology & Oncology, Hospital Clinic, Barcelona, Spain
- Renate Arnold
- Medizinische Klinik m. S. Hämatologie/Onkologie, Charité Universitätsmedizin Berlin, Germany
- Theo de Witte
- Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, the Netherlands
- Marie Robin
- Department of Hematology – BMT, Hôspital St. Louis, Paris, France
- Nikolaus Kröger
- Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany
- DOI
- https://doi.org/10.3324/haematol.2017.168716
- Journal volume & issue
-
Vol. 103,
no. 2
Abstract
No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1–5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8–21.2%). Shorter remission after transplantation (P
